News
FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback